New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the doses compared to approved monthly maintenance ...

Eli Lilly and Company has developed an app for people living with Type II diabetes who use Trulicity, the company’s once-per-week injectable diabetes medication that also works with a click-activated ...

If approved, EBGLYSS would be a first-line biologic that offers the option of monotherapy with once every eight-week maintenance dosing in moderate-to-severe atopic dermatitis uncontrolled by topicals ...